摘要
目的:探讨干扰素、拉米夫定、阿德福韦酯三种药物对慢性乙型病毒性肝炎患者的治疗效果。方法:将近年来我院收治的123例慢性乙型病毒性肝炎患者随机分为三组,干扰素组,拉米夫定组,阿德福韦酯组,每组各41例。分别给予干扰素、拉米夫定、阿德福韦酯进行抗病毒治疗,48周后比较三组疗效。结果:三组患者在性别、年龄、病程、肝功能改变程度、并发症方面比较,差异均无统计学意义(均P>0.05)。干扰素组、拉米夫定组、阿德福韦酯组HBeAg转阴率分别为9.76%、29.27%、34.15%,HBV-DNA转阴率分别为36.59%、60.98%、56.09%,ALT复常率分别为41.46%、58.54%、68.29%,组间两两比较,差异均有统计学意义(均P<0.05),且拉米夫定组、阿德福韦酯组各项指标疗效均高于干扰素组。结论:拉米夫定、阿德福韦酯治疗慢性乙型病毒性肝炎,均为有效药物。
Objective：To explore the efficacy of the treatment on chronic hepatitis B by Interferon,Lamivudine and Ade-fovir dipivoxil.Methods：123 cases of chronic hepatitis B were randomly divided into three groups,Interferon group,Lamivudine group and Adefovir dipivoxil group,41 cases in each group,they were given the Interferon,Lamivudine and Adefovir dipivoxil respectively.Then compared the efficacy of the three groups.Results：The negative conversion rate of HBeAg in the Interferon group,Lamivudine group and Adefovir dipivoxil group was respectively 9.76%,29.27%,34.15%,the negative conversion rate of HBV-DNA was respectively 36.59%,60.98% and 56.09%,the normalization rate of ALT was respectively 41.46%,58.54% and 68.29%,there were significant differences between each two groups.Conclusion：Lamivudine and Adefovir dipivoxil are effective drug in the treatment of chronic hepatitis B.
出处
《中国医药导报》
CAS
2011年第24期153-154,共2页
China Medical Herald
